Startup profile · funding coverage
Monogram Health funding, valuation and investors
Value-based in-home kidney and polychronic care delivery plus benefit management for health plans.
Keep track of Monogram Health
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Growth
$375M · January 2023
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$535M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Nashville, TN
Investors in latest funding
Other: TPG Capital , Frist Cressey Ventures , CVS Health , Cigna Ventures , Humana , Norwest Venture Partners
Overview
Monogram Health is a Nashville value-based specialty provider of in-home evidence-based care and benefit management for patients with polychronic conditions, including chronic kidney disease and ESRD. Founded/incubated with Frist Cressey Ventures in 2019 (Bill Frist chairs the board). Closed $160M Series B led by TPG (2021) and $375M growth capital (Jan 2023) including CVS Health, Cigna Ventures, Humana, Memorial Hermann, SCAN, TPG, Frist Cressey, Heritage Group, Norwest, and others. Operates value-based partnerships across dozens of states.
Why Monogram Health is interesting
Nashville kidney-care scale-up incubated by Frist Cressey Ventures: $375M growth raise (Jan 2023) with CVS, Cigna, Humana, TPG — proof of Middle Tennessee health-services venture density.
Product & use cases
Combines in-home clinical care teams with tech-enabled disease/case management, utilization management, and medication therapy management under value-based contracts with plans and risk-bearing providers.
- Medicare Advantage and commercial plans managing CKD/ESRD cost and outcomes
- Slowing kidney disease progression and improving home-based care access
- Polychronic patients needing coordinated specialty + primary care in-home
Key facts
- Growth (Jan 2023): $375M with CVS, Cigna Ventures, Humana, TPG, Frist Cressey, Norwest, others
- Series B (Jun 2021): $160M led by TPG; FCV and Norwest participated
- Incubated/founded with Frist Cressey Ventures (2019); Bill Frist board chair
- In-home nephrology + polychronic care model across 30+ states (company materials)
Funding history (newest first)
Growth
2023-01 $375M- TPG Capital (participant)
- Frist Cressey Ventures (participant)
- CVS Health (participant)
- Cigna Ventures (participant)
- Humana (participant)
- Norwest Venture Partners (participant)
Series B
2021-06 $160M- TPG Capital (lead)
- Frist Cressey Ventures (participant)
- Norwest Venture Partners (participant)
- Humana (participant)
Investors in our directory
Funds linked from Monogram Health's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Kidney-specialty VBC operator with plan partnerships and FCV healthcare network — not a pure SaaS navigation layer.
-
Somatus / Strive Health direct
Value-based kidney care competitors.
-
DaVita / Fresenius care models incumbent
Dialysis incumbents expanding upstream CKD programs.
-
Generic care management vendors adjacent
Utilization management without in-home nephrology delivery.
Notable stories
- FCV frames Monogram as a Nashville success story it incubated — growth capital funded national deployment of in-home kidney and polychronic care (fcventures.com).
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Monogram Health's financing or category context.
FAQs about Monogram Health
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.